Zetsin Pharmaceuticals Donafini and anti-PD-1 monoanti-combination therapy have been approved for clinical trials.

On July 9, Zesun Pharmaceuticals announced that it had recently received a "Notice of Clinical Trials" approved by the State Drug AdministrationThe relevant situation announcement is as follows:, the basic situation of the drug
toluene sulfonate Doofini tablets (hereinafter referred to as "Donafini") is the development of the oral multi-target, multi-kinase inhibitor class small molecular anti-tumor drugs, belong to the first class of new drugs, the company has independent intellectual property rightsPreclinical pharmacological studies confirm that Donovani can inhibit the activity of VEGFR, PDGFR and other receptorty tyrosine kinases, but also can directly inhibit various Raf kinases, and inhibit downstream Raf/MEK/ERK signaling pathways, inhibit tumor cell proliferation and tumor formation, play a multi-inhibition, multi-target blocking antitumor effectDonafini's first clinical trial application was accepted in October 2011, and The Phase III clinical phase of Donafini's first-line treatment for advanced liver cancer has been completed and a new drug application has been submittedAt the same time, clinical studies of Phase III clinical studies on the treatment of advanced colorectal cancer and iodine refractive differentiation thyroid cancer, and clinical studies of Doafeni and anti-PD-1 monoantiapiving advanced liver cell cancer are under wayTrepri synofre injection is a recombinant humanized anti-PD-1 monoclonal antibody injection developed by Shanghai Junshi Biopharmaceutical Technology Co., Ltd., approved by the State Drug Administration for sale in China on December 17, 2018 for local progression or metastatic melanoma after the failure of previous standard treatmentsSource: Zei Pharmaceuticals Announcement.